Zydus Cadila gets USFDA nod to market generic cancer drug in US

By: |
November 20, 2021 3:00 PM

The drug will be manufactured at the group's injectables manufacturing facility, tbe drug maker said.

zyndus cadila, cancer drug, market drg in US, US Food and Drug Administration, myelodysplastic syndromes, injectable manufacturing facilitiesThe drug will be manufactured at the group's injectables manufacturing facility. (Representative Image)

Drug firm Zydus Cadila on Saturday said it has received approval from the US health regulator to market Decitabine injection, used to treat certain types of cancers, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) to Decitabine for Injection in the strength of 50 mg/vial single-dose vial, Zydus Cadila said in a statement. Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer.

The drug will be manufactured at the group’s injectables manufacturing facility, tbe drug maker said.

The Zydus group now has 326 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04, it added.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Credit card spends jump 12% to cross Rs 1 lakh crore mark for first time
2MeitY releases national strategy on blockchain for its adoption in govt systems
3CSR funds meant for local development, should not be diverted for any other purposes: Jairam Ramesh